TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

KYOWA KIRIN

OncologyNeurologyMetabolic
Biotech

KYOWA KIRIN is a biotechnology company focused on Oncology, Neurology, Metabolic. Key products include NOURIANZ.

1997
Since
4
Drugs
-
Trials
4
Approved (2yr)

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 35%
1 drugs Phase 3: 1 Phase 2: 6 Phase 1: 12
Neurology 21%
1 drugs Phase 3: 1 Phase 2: 2 Phase 1: 6
Metabolic 20%
0 drugs Phase 3: 4 Phase 2: 1 Phase 1: 1
Immunology 19%
0 drugs Phase 3: 3 Phase 2: 1 Phase 1: 4
Gastroenterology 5%
0 drugs Phase 2: 1 Phase 1: 3

Pipeline Strength Pro

Loading...